Who Will Enroll? Predicting Participation in a Phase II AIDS Vaccine Trial
- 1 July 2001
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (3) , 281-288
- https://doi.org/10.1097/00126334-200107010-00011
Abstract
Background:The problems of underenrollment and selective enrollment may undermine AIDS vaccine trials. If prospective study subjects' stated willingness to participate (WTP) in hypothetical vaccine trials predicts future enrollment, then measuring WTP before recruitment may enhance the enrollment in, and ethics of, such trials. Methods:We prospectively studied changes over an 18-month period in the stated WTP in, and knowledge of, a hypothetical AIDS vaccine trial among 610 Philadelphia residents at high risk for HIV infection. Of these people, 499 were subsequently recruited to participate in an actual, phase II AIDS vaccine trial. We used multivariable logistic regression and the area under the receiver-operating characteristic (ROC) curve to model predictors of actual enrollment. Results:Actual enrollment rates were 8.3%, 6.8%, 15.8%, and 29.0% among those who had initially said they were “definitely not,” “probably not,” “probably,” and “definitely” willing to participate, respectively (p = .006). The area under the ROC curve was 0.65, indicating a modest ability of stated WTP to differentiate those who enroll from those who do not. Knowledge of basic vaccine trial concepts, though unrelated to enrollment, increased over an 18-month period with repeated education sessions (p < .0001), whereas stated WTP declined over this same period (p < .0001). Conclusion:Although other factors not captured by stated WTP may also influence future enrollment, prospectively assessing stated WTP may augment the validity of the informed consent process, help prevent underenrollment, and clarify the population from which the study sample is drawn. Address correspondence and reprint requests to Scott D. Halpern, Center for Clinical Epidemiology and Biostatistics, 108 Blockley Hall. 423 Guardian Drive. Philadelphia. PA 19104-6021 U.S.A.; e-mail: [email protected] Manuscript received December 7, 2000; accepted April 11. 2001. © 2001 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 25 references indexed in Scilit:
- Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?The Lancet, 2000
- What Makes Clinical Research Ethical?JAMA, 2000
- Assessment of the Changing Willingness to Participate in Phase III HIV Vaccine Trials Among Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Willingness to Participate in HIV-1 Vaccine Efficacy Trials and the Effect of Media Events Among Gay and Bisexual Men in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.Journal of Clinical Oncology, 1994
- Recruitment experience in clinical trials: Literature summary and annotated bibliographyControlled Clinical Trials, 1987
- Randomization Designs in Comparative Clinical TrialsNew England Journal of Medicine, 1984
- Some adaptive strategies for inadequate sample acquisition in veterans administration cooperative clinical trialsControlled Clinical Trials, 1980
- Statistics and ethics in medical research: III How large a sample?BMJ, 1980
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978